Life Biosciences is pushing cellular rejuvenation into the clinic with ER-100, an experimental gene ...

Resting brain stem cells hardly differ from normal astrocytes, which support the nerve cells in the brain. How can almost identical cells perform such different functions? The key lies in the ...

Lactate, once considered a metabolic waste product, is now recognized as a key regulator of cellular homeostasis and disease progression. In gynecological malignancies-including ovarian, cervical, and ...

Diffuse midline glioma (DMG), H3K27-altered, is a lethal pediatric high-grade tumor, lacking effective treatment options, primarily depending on clinical trials. Epigenetic agent-based immunotherapy ...

Metabolic syndrome (MetS) is a multifaceted disorder that impacts approximately 20–25% of the global population. This syndrome encompasses a range of conditions, including obesity, type 2 diabetes ...

Understanding the mechanisms of low temperature-induced epigenetic reprogramming may therefore inform cancer treatments. All in all, this research shows that the genome isn't a fixed instruction ...

Age-related memory decline and neurodegenerative diseases like Alzheimer's are often thought of as irreversible. But the brain is not static; neurons continually adjust the strength of their ...

A novel gene therapy that leads to cellular rejuvenation could restore vision after non-arteritic anterior ischemic optic neuropathy (NAION) and glaucoma. The technique is based on a reprogramming ...

Combined epigenetic and immune checkpoint therapy altered the tumour microenvironment in platinum-resistant ovarian cancer.

The race to slow, halt, or even reverse aging has moved from science fiction into the regulatory record. A Harvard-linked startup, Life Biosciences, has secured clearance from the U.S. Food and Drug ...